title: High-dose chemotherapy for the treatment of breast and ovarian cancer.
abstract: Breast cancer is currently the primary indication for high-dose chemotherapy with autologous hematopoietic progenitor cell support. Recent advances include the first randomized trial comparing high-dose chemotherapy with conventional-dose chemotherapy in patients with metastatic disease, new and improved methods for detection of tumor cells in the autologous graft, new high-dose chemotherapy regimens, new trials exploring multicycle high-dose chemotherapy, and the development of prognostic factors that may predict the outcome of patients who receive this treatment. In patients with ovarian cancer, a recently activated intergroup randomized study of high-dose chemotherapy compared with conventional dose chemotherapy should help clarify the role of high-dose chemotherapy for the treatment of this disease.
authors.affiliation: University of Colorado Health Sciences Center, Denver 80220, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Cagnoni
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D010051:Ovarian Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents